Fluoropyrimidine-induced cardiotoxicity

Andrada Larisa Deac, Claudia Cristina Burz, Ioana Corina Bocsan, Anca Dana Buzoianu

Abstract
Cardio-oncology is a discipline based on early screening, monitoring, and treating chemotherapy-induced cardiotoxicity. There are many chemotherapeutics known for their cardiac toxic effects, including fluoropyrimidines. Fluoropyrimidine represents the cornerstone of many types of cancer and each year almost two million cancer patients undergo this treatment. Fluoropyrimidine-induced cardiotoxicity can be manifested in several forms, from angina pectoris to sudden death. This paper is a review of how the cardiotoxicity of fluoropyrimidines is presented, the mechanisms of its occurrence, its diagnosis, and management.

Key Words: Fluoropyrimidines; Cancer treatments; Cardiotoxicity; Rechallenge; Prevention; Antidote

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
INTRODUCTION

Fluoropyrimidine-based treatments are one of the most frequently used methods of chemotherapy worldwide. The fluoropyrimidine drugs include 5-fluouracil (5-FU), Capecitabine, Tegafur, S-1, and TAS-102. Fluoropyrimidines are useful in the treatment of head and neck cancer, breast cancer, esophageal cancer, gastric cancer, pancreatic cancer, and colorectal cancer, and it is estimated that more than 2 million patients are being treated with fluoropyrimidines\[^{[1-3]}\]. The toxicity associated with fluoropyrimidine chemotherapy affects almost 30% of patients with more than 10% severe toxicity (CTC-AE grade ≥ 3) requiring hospitalization, and in 0.5%-1% of cases, the toxicity is lethal\[^{[4]}\].

The most known cause of fluoropyrimidine toxicity is the deficiency of dihydropyrimidine dehydrogenase (DPD), a crucial enzyme in fluorouracil metabolism, which is encoded by the \(DPYD\) gene\[^{[6]}\]. DPD levels show an important intra- and inter-individual variability which influences the patient’s response to fluoropyrimidine in terms of efficacy, resistance, and toxicity\[^{[8]}\]. Deleterious polymorphism of \(DPYD\) represents the main cause of DPD deficiency. The most common \(DPYD\) variants associated with toxicity during treatment with fluoropyrimidine are \(DPYD^*2A\) (IVS14+1G>A, c.1905+1G>A), \(DPYD^*9B\) (c.2846A>T), \(DPYD^*13\) (c.1679T>G), and HapB3 (c.1129-5923C>G)\[^{[6-8]}\].

Fluoropyrimidine toxicity can be manifested through hematological non-cumulative toxicity most common in bolus infusion (anemia, neutropenia, thrombocytopenia), immediate digestive toxicity (nausea, vomiting, diarrhea, stomatitis, ileitis), alopecia in the case of continuous perfusion, thrombophlebitis and photosensitivity along the vein pathway, neurological toxicity if in high doses (cerebellar ataxia), ophthalmological toxicity through tear excretion (conjunctivitis, tear hypersecretion), skin toxicity usually aggravated by sun exposure (hand-foot syndrome, hyperpigmentation, hives, rash), and reversible cardiac toxicity following continuous perfusion (angina pectoris, unstable angina pectoris, arrhythmias, myocardial infarction, heart failure, myocardial necrosis)\[^{[8]}\].

CARDIOTOXICITY GENERALITIES

Chemotherapy-related cardiac dysfunction is one of the chemotherapy side effects that can appear even 20 years after treatment with an incidence of 10%-15%. Chemotherapy-related cardiotoxicity can be due to the direct effect of chemotherapeutic agents on the entire cardiovascular system or indirectly through thrombogenic status or alteration of hemodynamic flow during treatment\[^{[11]}\]. The European Society of Cardiology (ESC) defines cardiotoxicity as the decrease in left ventricular ejection fraction with more than 10% of the normal value or a decrease of more than 15% of the overall longitudinal deformation of the cord while preserving the ejection fraction\[^{[12]}\]. Two types of cardiotoxicity have been described: (1) Type I, irreversible, dose-related, and caused by free radical formation, oxidative stress and myocyte fiber rearrangements, and mitochondrial dysfunction, e.g., anthracycline-induced toxicity; and (2) Type II, reversible, not dose-related and is not associated with structural changes and can be induced by biological therapy, e.g., Trastuzumab\[^{[12-13]}\]. Cardiotoxicity manifests itself in the form of hypertension, arrhythmias, myocardial dysfunction, coronary artery disease, sinus node dysfunction, atrioventricular block, thromboembolic disease, peripheral vascular disease and stroke, pulmonary hypertension, pericardial complications, and heart failure\[^{[12,13]}\].

FLUOROPYRIMIDINE-INDUCED CARDIOTOXICITY

Fluoropyrimidines produce type II, reversible cardiotoxicity. The incidence of fluoropyrimidine-induced cardiotoxicity ranges from 1% to 18%\[^{[14-17]}\]. The most common symptom of fluoropyrimidine cardiotoxicity is chest pain\[^{[18-19]}\]. Other symptoms that may occur are palpitations, dyspnea, hypertension, or hypotension, while less common manifestations include myocardial infarction, reversible
cardiomyopathy, myopericarditis, congestive heart failure, tachyarrhythmias, coronary dissection, cardiogenic shock, and sudden death. Another manifestation of cardiotoxicity is the development of silent cardiac ischemia. Prospective and retrospective studies have reported electrocardiography (ECG) changes of silent ischemia ranging from 4% to 88%.

Among the proposed risk factors for fluoropyrimidine cardiotoxicity are older age, concurrent radiotherapy or history of chest radiotherapy, concurrent administration of cardiotoxic drugs, history of cardiovascular diseases or the presence of cardiovascular risk factors such as hypertension, dyslipidemia, diabetes mellitus, and smoking. Studies have shown that the continuous infusion of 5-FU compared with bolus administration is associated with a higher incidence for cardiac adverse events. Kosmas et al. also demonstrated that the addition of Leucovorin (LV), a potentiator of 5-FU activity in 24 h continuous infusion and five days of 5-FU, may increase the incidence of cardiac adverse events (13%) compared with the same schedule of 5-FU administration but without LV addition (5%). Furthermore, de Forni et al. examined 367 patients receiving a continuous infusion of 5-FU at doses between 600-1000 mg/m²/day and showed higher toxicity at doses more than 800 mg/m²/day. Symptoms usually appear in the first 72 h during the first cycle of 5-FU, but they can develop any time during the course of treatment and even a couple of days after the end of treatment.

MECHANISM OF CARDIOTOXICITY

The pathogenesis of fluoropyrimidine-induced cardiotoxicity has not been fully elucidated. Several hypotheses have been proposed, such as vasoconstriction, direct myocardial toxicity, endothelial dysfunction, and a hypercoagulable status leading to thrombosis, all of them leading to cardiac damage (Figure 1).

The coronary vasospasm and the ischemic events it produces are probably the most studied cardiac adverse events of fluoropyrimidines. Patients usually present symptoms and signs of acute coronary syndrome, possibly increased troponin in blood levels, and often ST segment changes on ECG. ST-T wave changes are seen in 65% of cases and elevated cardiac enzymes only in 7%.[29] Luwaert et al. in one of the first reports of coronary vasospasm associated with fluoropyrimidine cardiotoxicity, performed angiography during the 5-FU infusion and observed vasospasm of the left circumflex artery, which was resolved by an intracoronary injection of isosorbide dinitrate. Despite this, coronary angiography was often normal without any evidence of a thrombotic event.[30] Morselli et al. showed that the activation of protein kinase C (PK-C), a subcellular mediator of vascular smooth muscle tone, can also be a mediator of 5-FU-induced vasoconstriction and 5-FU causes direct endothelium-independent vasoconstriction of vascular smooth muscle in vitro. In other studies, Thyss et al. and Porta et al. found high levels of endothelin-1, a regulatory vasoconstrictor, in patients with 5-FU-induced cardiotoxicity. The vasodilator therapy included nondihydropyridine calcium channel blockers such as Verapamil or Diltiazem, and nitrates have been shown to be effective in resolving symptoms and ECG changes.[31]

Another mechanism of fluoropyrimidine cardiotoxicity is represented by direct myocardial injury highlighted by global systolic dysfunction. Following a ventricular biopsy, Kuropak et al. reported the role of sarcoplasmic reticulum dilatation in cardiotoxicity, a mechanism similar to the cardiotoxicity of anthracyclines.

The accumulation of alpha-fluoro-beta-alanine (FbAL), a metabolite of 5-FU metabolism, which is converted to fluoroacetate and then to fluorocitrate, can cause an impairment in the Krebs cycle leading to citrate accumulation and downstream depletion of ATP resulting in ischemia.[32,33] FbAL involvement as a direct mediator of cardiotoxicity was demonstrated by Muneoka et al. who showed elevated levels of FbAL in a patient suffering from a myocardial infarction after administration of 5-FU. The same patient was later treated with S-1, a combination of fltorafur (FT), oxonic acid and gimeracil at a molar ratio of 1:0.4:1, and did not experience any associated cardiac adverse effects.[34,35] Kwakman et al. demonstrated in a series of seven patients that the rechallenge with S-1 after Capecitabine-induced cardiotoxicity was without recurrent cardiac side effects. An explanation for the lack of associated cardiotoxicity of S1 is due to gimeracil, a DPD-inhibitor, which increases the concentration of 5-FU, leading to a lower concentration of FbAL.[36]

The dysfunction of vascular endothelium followed by thrombosis, independent of vasoconstriction, seems to be a possible mechanism associated with fluoropyrimidine-
induced cardiotoxicity. Many studies on animals have analyzed the effect of 5-FU on vascular endothelial cells and showed direct endothelial dysfunction and platelet and fibrin accumulation\cite{34}. Kuzel et al\cite{35} reported an increase in fibrinopeptide A and a decrease in protein C in the presence of 5-FU, which together confer a more susceptible environment for thrombus formation.

In another study, Spasojević et al\cite{36} demonstrated that 5-FU can cause changes in the shape of the erythrocyte membrane and lead to increased blood viscosity and decreased ability to carry and release oxygen, thus causing myocardial ischemia. Focaccetti et al\cite{37} demonstrated increased reactive oxygen species (ROS) in cardiomyocytes and endothelial cells, leading to 5-FU induced apoptosis. In guinea pig hearts treated with 5-FU, decreased levels of superoxide dismutase and glutathione peroxidase have been observed, supporting the theory of oxidative stress\cite{38}. Eskandari et al\cite{39} support the same theory in their study and demonstrated that fluoropyrimidine cardiotoxicity was associated with the formation of ROS, depletion of glutathione and lipid peroxidation, resulting in an increase in oxidative stress, which correlated with mitochondrial dysfunction that triggers caspase-3 and activates apoptosis or necrosis.

Another mechanism suggested by Karabay et al\cite{40} is Kounis syndrome, an acute coronary syndrome caused by an allergic reaction which can precipitate the release of inflammatory mediators that can break the atherosclerotic plaques caused by 5-FU exposure, causing coronary vasospasm which partially responds to antihistamine and corticosteroid therapy.

**DIAGNOSIS OF FLUOROPYRIMIDINE-INDUCED CAR Di TOXICITY**

There is no specific test for the diagnosis of fluoropyrimidine-induced cardiotoxicity, and it is usually guided by anamnensis of cardiovascular risk factors and diseases followed by a cardiologic examination, electrocardiography, cardiac enzymes, and echocardiography.

In cancer patients with previous coronary artery disease and indications of fluoropyrimidine-based chemotherapy, additional attention must be paid to risk factors such as smoking, hypertension, diabetes mellitus, and dyslipidemia followed by pharmacological treatment, before starting treatment with fluoropyrimidines\cite{41}.

Cardiac 12-lead ECG monitoring is the most feasible method for early detection of cardiac adverse events during the course of 5-FU chemotherapy\cite{41}. ECG is recommended for all patients before and during chemotherapy. The most common findings on ECG are ST elevation, ST depression, QT prolongation and inverted T waves\cite{41}. Holter monitoring represents a method with a higher sensitivity, but no recommendations have been made for this technique. ECG changes may occur early during the continuous infusion of 5-FU or in the first days of Capecitabine.
Deac AL et al. Fluoropyrimidine-induced cardiotoxicity

The brain natriuretic peptide (BNP), troponin I and T (TnI and TnT) and creatine phosphokinases (CK and CK-MB) are well known markers for the diagnosis and prognosis of heart diseases. TnI is a protein specific to the myocardial tissue and a component of the troponin protein complex; an increase in serum TnI level is an early and specific sign of myocardial injury, but no significant changes have been found in patients with fluoropyrimidine-induced cardiotoxicity[49]. The European Society of Medical Oncology (ESMO), in their clinical practice guidelines regarding fluoropyrimidine cardiotoxicity, recommends monitoring of TnI and brain natriuretic peptide (BNP) in patients with symptoms or signs of cardiac ischemia as a grade C III/IV level of evidence[44]. Holubec et al[29] determined BNP and TnI before and after 5-FU chemotherapy and showed increased levels of TnI in 57% of cases and BNP in 57% of cases, but no correlations have been made with clinical signs of cardiotoxicity. Data on the clinical relevance of cardiac biomarkers are very controversial; several studies have shown that BNP and troponins remain unchanged despite the occurrence of cardiac adverse events[42,45]. In only one study, out of 26 patients who experienced cardiac adverse events, seven had an increase in CK-MB level; the remaining studies did not show changes in CK-MB in patients with cardiotoxicity[49,50].

Another way to assess fluoropyrimidine cardiotoxicity is by echocardiography and imaging techniques. Fluoropyrimidine-induced cardiotoxicity can affect ventricular systolic and diastolic kinetics by reducing left ventricular ejection fraction[46]. Evidence of the role of echocardiography is also controversial; some authors failed to detect changes in diastolic and systolic function, while others such as Turan et al[47] and Wacker et al[48] found a significant correlation between a decrease in diastolic and systolic function and fluoropyrimidine cardiotoxicity in 18.7% of patients after the first cycle and in 10.5% of patients three months after chemotherapy[42,43].

MANAGEMENT

In cases of acute fluoropyrimidine cardiotoxicity, the first step should be to stop the treatment immediately and treat the symptoms with antianginal drugs such as nitrates, calcium channel blockers, and antiplatelets[44]. Symptom cessation has been shown in 69% of cases[44]. For high-risk patients with suspected acute coronary syndrome, the American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend an urgent coronaryography with revascularization, and for low risk patients with persistent minor or mild symptoms, it is suggested to consider a stress test or coronary computed tomography angiography[42,43].

Rechallenging a patient with fluoropyrimidine may cause a recurrence of cardiac symptoms in 45%-90% of patients and a death rate of 18%-52%. Clavel et al[49] reported 4 cases of myocardial necrosis and 4 cases of cardiogenic shock in a series of 28 rechallenged patients. Given all the existing scientific evidence, several strategies have been proposed depending on what other therapeutic options exist and the need to keep fluoropyrimidines in patient treatment. If the patient still needs fluoropyrimidine-based chemotherapy, the following strategies should be considered: (1) Switch from continuous infusion to 5-FU bolus administration; (2) Dose reduction along with antianginal drug prophylaxis; and (3) Other oral fluoropyrimidines such as uracil-tegafur or S-1, both drugs contain either uracil which competes with 5-FU for DPD and therefore reduces the degradation of 5-FU into FbAL, or gimeracil which as we have seen before is a DPD inhibitor and also prevents FbAL formation[49]. Even if we know about the possible benefit of those two prodrugs, we still need more studies to prove the lower cardiotoxicity and trials of equalization with 5-FU and Capecitabine. Another option is TAS-102, the combination of trifluridine (TDF) and tipiracil, the last fluoropyrimidine approved in chemorefractory colorectal cancer. TDF exhibits two anti-tumor mechanisms: Inhibition of TS and the creation of single-strand DNA breaks by incorporating the triphosphate form into DNA in the place of thymidine[49]. The addition of tipiracil inhibits trifluridine degradation and increases bioavailability[46]. The fact that TAS-102 is not metabolized by DPD explains the lack of cardiac adverse events[49].

Clasen et al[51] in a case series of 11 patients with previous fluoropyrimidine cardiotoxicity, successfully rechallenged with the same drug, and based on their experience, they made the following recommendations: (1) Switch from continuous administration to bolus; (2) Pretreatment with isosorbide mononitrate for 3 to 4 h and extended-release nifedipine before 5-FU administration; (3) Treatment with short-
acting diltiazem and sublingual nitroglycerin during the treatment with 5-FU; (4) Posttreatment with nifedipine and isosorbide mononitrate 12 h after the first dose of antianginal pretreatment; and (5) Posttreatment with nifedipine 24 h after the first dose.

Another alternative to fluoropyrimidine is represented by Raltitrexed (Tomudex), a quinazoline folate analogue, which inhibits thymidylate synthase (TS), thereby blocking DNA synthesis\cite{58}. The results of two prospective studies proposed Raltitrexed as an option for colorectal cancer patients with cardiovascular risk factors or fluoropyrimidine cardiotoxicity. Ransom et al\cite{59} published the final results of the Australasian Gastrointestinal Trials Group ARTIC study and reported no cardiac adverse effects attributed to Raltitrexed in 42 patients who previously experienced fluoropyrimidine cardiotoxicity. In the second study, Raltitrexed was used in 111 colorectal cancer patients who presented fluoropyrimidine cardiotoxicity and important cardiovascular risk factors\cite{60}. The study reported five patients who experienced cardiac adverse events during treatment with Raltitrexed\cite{60}. Both of these studies indicate that Raltitrexed can be a safe alternative in patients after cardiac adverse events.

In the desire to counterbalance the severe side effects or fluoropyrimidine overdose, uridine triacetate (UT, Vistogard) was approved by the FDA in 2015 as an antidote based on two open-label, single-arm trials which demonstrated a survival benefit in 96% of cases\cite{61,62}. Uridine triacetate is an oral pyrimidine analogue of uridine, which competes with fluorouridine-triphosphate incorporation into RNA and this way improves fluoropyrimidine toxicity\cite{17,61,62}. Uridine triacetate can be used in the first 96 h after the last dose of 5-FU or Capecitabine for early-onset, severe or life-threatening toxicity such as severe neutropenia, gastrointestinal toxicity or cardiotoxicity unresponsive to drug cessation and antianginal therapy (Table 1)\cite{62}.

Phenotyping and genotyping DPD activity before starting the treatment with fluoropyrimidine can be useful to detect the patients who are already more predisposed to experiencing severe adverse events. In a case report, Saif et al\cite{64} showed the presence of both DPYD and TYMS gene mutations in a patient who developed a severe Takotsubo cardiomyopathy after receiving fluoropyrimidine treatment. We need more studies to evaluate the possible correlation between DDP deficiency and cardiotoxicity.

**CONCLUSION**

Fluoropyrimidine cardiotoxicity may be more common than is currently diagnosed due to the multiple indications of this class. Despite the fact that 5-FU and Capecitabine cardiotoxicity is not very common, it can be unpredictable and sometimes fatal. Even if some of the fluoropyrimidine cardiotoxicity mechanisms are known, we still need more studies to discover new mechanisms or to explore the mechanisms already known and the possible relationship with DPYD mutation or other genes involved in the metabolism of fluoropyrimidines. There is currently no consensus on the treatment and prophylaxis of these adverse events, the only certainty is the need for immediate discontinuation of fluoropyrimidine chemotherapy and treatment of symptoms. Rechallenging the patient with 5-FU or Capecitabine is feasible, but it comes with certain risks such as the recurrence of cardiac toxicity or more severe forms of it. If a decision is made to continue this treatment, antianginal therapy may prevent ischemic events. In such a scenario, dose reduction is also recommended. We still need more studies and tools to identify the patients who will develop cardiotoxicity due to fluoropyrimidine-based chemotherapy and to determine how we can prevent it.
Table 1: Management of fluoropyrimidine-induced cardiotoxicity and rechallenge

| Management of acute cardiotoxicity | Rechallenge with fluoropyrimidine | Antidote |
|-----------------------------------|-----------------------------------|----------|
| Stop fluoropyrimidine chemotherapy | Switch from continuous infusion to bolus administration | Uridine triacetate |
| Administration of antianginal drugs and antiplatelets | Dose reduction with antianginal drugs administration: (1) Pretreatment 3 to 4 h before fluoropyrimidine; (2) Administration during the treatment with 5-FU; (3) Posttreatment 12 or 24 h after fluoropyrimidine | |
| Monitor patient’s cardiac enzymes, ECG | Use of alternative fluoropyrimidine agents (S1, TAS-102) | |
| Coronarography with revascularization if acute coronary syndrome is suspected | Use of alternative non-fluoropyrimidine agents | |
| Stress test or coronary CT angiography in patients with persistent minor or mild symptoms | | |

ECG: Electrocardiography; CT: Computed tomography; 5-FU: 5-fluorouracil.

REFERENCES

1. Fragoulakis V, Roncato R, Fratte CD, Ecca F, Bartakoula M, Innocenti F, Toffoli G, Cecchin E, Patrinos GP, Mitropoulou C. Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity. Am J Hum Genet 2019; 104: 1158-1168 [PMID: 31155283 DOI: 10.1016/j.ajhg.2019.04.017]

2. Henricks LM, Opdam FL, Beijnen JH, Cats A, Schellens JHM. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. Ann Oncol 2017; 28: 2915-2922 [PMID: 29045513 DOI: 10.1093/annonc/mdx411]

3. Meulendijks D, Cats A, Beijnen JH, Schellens JH. Improving safety of fluoropyrimidine chemotherapy by individualized treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice? Cancer Treat Rev 2016; 50: 23-34 [PMID: 27589823 DOI: 10.1016/j.ctrv.2016.08.002]

4. Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Frohlich TK, Amstutz U, Largiadèr CR, Jennings BA, Marinati AM, Sanderson JD, Kleibl Z, Kleiblова P, Schwab M, Zanger UM, Palles C, Tomlinson I, Gross E, van Kuilenburg AB, Punl CL, Koopman M, Beijnen JH, Cats A, Schellens JH. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015; 16: 1639-1650 [PMID: 26603945 DOI: 10.1016/S1470-2045(15)00286-7]

5. Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caulde KE, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther 2018; 103: 210-216 [PMID: 29152729 DOI: 10.1002/cpt.911]

6. Lam SW, Guchelaar HJ, Boven E. The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev 2016; 50: 9-22 [PMID: 27569869 DOI: 10.1016/j.ctrv.2016.08.001]

7. Wige TJ, Tsvetkova EV, Welch SA, Kim RB. DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report. Pharmaceutics 2019; 11 [PMID: 31052357 DOI: 10.3390/pharmaceutics1050199]

8. Terrazzino S, Cargini S, Del Re M, Danesi R, Canonico PL, Genazzani AA. DPYD IVS1+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics 2013; 14: 1255-1272 [PMID: 23930673 DOI: 10.2217/pgs.13.116]

9. Del Re M, Cinieri S, Michelucci A, Salvadori S, Loupakis F, Schirripa M, Cremoni L, Crucita S, Barbara C, Di Leo A, Latinoan TP, Pietrantonio F, Di Donato S, Simi P, Passardi A, De Braud F, Altavilla G, Zamagni C, Bordonaro R, Butera A, Maiello E, Pinto C, Falcone A, Mazzotti V, Morganti R, Danesi R. DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. Pharmacogenomics J 2019; 19: 556-563 [PMID: 30723313 DOI: 10.1038/s41397-019-0077-1]

10. Chu E, DeVita Jr VT. Physicians’ Cancer Chemotherapy Drug Manual. Sudbury, Massachusetts: Jones and Bartlett, 2020

11. Quaranta S, Thomas F. Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics. Therapie 2017; 72: 205-215 [PMID: 28262261 DOI: 10.1016/j.therap.2017.01.005]

12. Jain D, Aronow W. Cardiotoxicity of cancer chemotherapy in clinical practice. Hosp Pract (1995) 2019; 47: 6-15 [PMID: 30270693 DOI: 10.1080/21548331.2018.1530831]

13. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboys V, Asteigiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T, Molyd D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Zamorano JL, Aboys V, Achenbach S, Agewall S, Badimon L, Barón-Esquivias G,
Baumgartner H, Bas JJ, Bueno H, Carej S, Dean V, Erol Ç, Fitzsimons D, Gaemperli O, Kirchhof P, Kolh P, Lancellotti P, Lip GY, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Roffi M, Torbicki A, Vaz Carneiro A, Windecker S, Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); Document Reviewers. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail 2017; 19: 9-42 [PMID: 27956576 DOI: 10.1002/ejhf.564]

Shah CP, Moreh JS. Cardiotoxicity due to targeted anticancer agents: a growing challenge. Ther Adv Cardiovasc Dis 2019; 13: 1753944719843435 [PMID: 30995890 DOI: 10.1177/1753944719843435]

Teske AJ, Linschoten M, Kamphuis JAM, Naaktgeboren WR, Leiner T, van der Wall E, Kabul J, van Rhenen A, Doevendans PA, Cramer MJ, Asselbergs FW. Cardio-oncology: an overview on outpatient management and future developments. Neth Heart J 2018; 26: 521-532 [PMID: 30141030 DOI: 10.1007/s12471-018-1148-7]

Yuan C, Parekh H, Allegra C, George TJ, Starr JS. 5-FU induced cardiotoxicity: case series and review of the literature. Cardiooncology 2019; 5: 13 [PMID: 32154019 DOI: 10.1186/s40959-019-0048-3]

Kanduri J, More LA, Godishala A, Asnani A. Fluoropyrimidine-Associated Cardiotoxicity. Cardiol Clin 2019; 37: 399-405 [PMID: 31587781 DOI: 10.1016/j.ccl.2019.07.004]

Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev 2013; 39: 974-984 [PMID: 23582737 DOI: 10.1016/j.ctrv.2013.03.005]

Kosmas C, Kallistratos MS, Kopterides P, Syris A, Skopelitis H, Mylonakis N, Karabelis A, Tsavaris N. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2000; 134: 75-82 [PMID: 17633232 DOI: 10.1007/s00432-000-0250-9]

Lestuzzi C, Trutuferi L, Viel E, Buonadonna A, Vescalheiro E, Berretta M, Flori G. Fluoropyrimidine-Associated Cardiotoxicity: Probably Not So Rare As It Seems. Oncologist 2020 [PMID: 32436298 DOI: 10.1634/theoncologist.2020-0053]

Bathina JD, Yusuf SW. 5-Fluorouracil-induced coronary vasospasm. J Cardiovasc Med (Hagerstown) 2010; 11: 281-284 [PMID: 19561527 DOI: 10.2459/JCM.0b013e32832a2934]

Luuwaert RJ, Descamps O, Majois F, Chaudron M, Beauduin M. Coronary artery spasm induced by 5-fluorouracil. Eur Heart J 1991; 12: 468-470 [PMID: 2040332 DOI: 10.1093/oxfordjournals.eurheartj.a059919]

Shoemaker IK, Arora U, Rocha Lima CM. 5-fluorouracil-induced coronary vasospasm. Cancer Control 2004; 11: 46-49 [PMID: 1474623 DOI: 10.1034/j.1752-1629.2001.100300.x]

Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasocconstriction of vascular smooth muscle. Cancer Res 1993; 53: 3028-3033 [PMID: 8391384]

Thyss A, Gaspard MH, Marsault R, Milano G, Frelin C, Schneider M. Very high endothelin plasma levels in patients with 5-FU cardiotoxicity. Ann Oncol 1992; 3: 88 [PMID: 1600678 DOI: 10.1093/oxfordjournals.annonc.a058084]

Porta C, Moroni M, Ferrari S, Nastasi G. Endothelin-1 and 5-fluorouracil-induced cardiotoxicity. Neoplasma 1998; 45: 81-82 [PMID: 9687887]

Farina A, Malafonti C, Valsecchi MA, Achilli F. Capecitabine-induced cardiotoxicity: when to suspect? J Cardiovasc Med (Hagerstown) 2009; 10: 722-726 [PMID: 19584743 DOI: 10.2459/JCM.0b013e32832bb9b1]

de Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L, Canal P, Chevereau C, Carrié D, Soulié P. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992; 10: 1795-1801 [PMID: 1403606 DOI: 10.1200/JCO.1992.10.11.1795]

Krupokat C, Griem K, Clark J, Rodriguez ER, Hutchinson J, Taylor SG 4th. Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report. Am J Clin Oncol 1999; 22: 466-470 [PMID: 10521060 DOI: 10.1097/00000421-199910000-00009]

Muneoka K, Shirar Y, Yokoyama N, Wakai T, Hatakeyama K. 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine. Int J Clin Oncol 2005; 10: 441-443 [PMID: 16369751 DOI: 10.1007/s10147-005-0516-7]

Peters GJ, Noordhuis P, Van Kuiilenburg AB, Schornagel JH, Gall H, Turner SL, Swart MS, Voorn D, Van Gennip AH, Wanders J, Holwerda U, Smid K, Giacone G, Funemoleu P, Van Groeningen CJ. Pharmacokinetics of S-1, an oral formulation of fluorouracil, oxonic acid and 5-chloro-2,4-dihydroxypyrimidine (molar ratio 1:0.4:1) in patients with solid tumors. Cancer Chemother Pharmacol 2003; 52: 1-12 [PMID: 12739060 DOI: 10.1007/s00280-003-0617-9]

Kwakman JJM, Baeus A, van Zweeden AA, de Mol P, Koopman M, Kok WEM, Punt CJA. Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm. Eur J Cancer 2017; 81: 130-134 [PMID: 28623776 DOI: 10.1016/j.ejca.2017.05.022]

Yamada Y, Hamaguchi T, Goto M, Muro K, Matsunami Y, Shimada Y, Shirao K, Nagayama S. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer 2003; 89: 816-820 [PMID: 12942110 DOI: 10.1038/sj.bjc.6601224]

Cwikel M, Eskilsson J, Wieslander JB, Stjernquist U, Albertsson M. The appearance of endothelium
in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. *Scanning Microsc* 1996; 10: 805-18; discussion 819 [PMID: 9813641]

35 **Kuzel T, Esparaz B, Green D, Kies M.** Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. *Cancer* 1990; 65: 885-889 [PMID: 2297659] DOI: 10.1002/10.002.1565.3-5.8-488; and-cancer25200650410-3.0.co;2-6

36 **Spasovecić M, Maksimović V, Zakrezewska J, Bacić G.** Effects of 5-fluorouracil on erythrocytes in relation to its cardiotoxicity: membrane structure and function. *J Chem Inf Model* 2005; 45: 1680-1685 [PMID: 16309273] DOI: 10.1021/ci050174e

37 **Focacetti C, Bruno A, Magnani E, Bartolini D, Principi D, Dallaglio K, Bucci EO, Finzi G, Sessa F, Noonan DM, Albini A.** Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. *PLoS One* 2015; 10: e0115686 DOI: 10.1371/journal.pone.0115686

38 **Durak I, Kararayaz M, Kavutcu M, Cimen MY, Kaçmaz M, Bilyükköşk E, Oztürk HS.** Reduced antioxidant defense capacity in myocardial tissue from guinea pigs treated with 5-fluorouracil. *J Toxicol Environ Health A* 2000; 59: 585-589 [PMID: 10777249] DOI: 10.1080/00984100100156709

39 **Eskandari MR, Moghaddam F, Shahraki J, Pourahmad J.** A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drug capcitabine. *Xenobiota* 2015; 45: 79-87 [PMID: 25034007] DOI: 10.3109/00498254.2014.942809

40 **Karabay CY, Gecmen C, Aung SM, Guler A, Candan O, Batgerel U, Kalayci A, Kırma C.** Is 5-fluorouracil-induced vasospasm a Kounis syndrome? *Perfusion* 2011; 26: 542-545 [PMID: 21628340] DOI: 10.1177/0267659111410347

41 **Francis N.** The need for routine monitoring of cardiac function in patients receiving 5-fluorouracil infusion. *Clin J Oncol Nurs* 2014; 18: 360-362 [PMID: 24867118] DOI: 10.1188/14.CJON.360-362

42 **Oztop I, Genez M, Oktan T, Yaren A, Altekin E, Turkser S, Yılmaz U.** Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers. *Jpn J Clin Oncol* 2004; 34: 262-268 [PMID: 15231861] DOI: 10.1093/jjco/hby047

43 **Koca D, Salman T, Unek IT, Oztop I, Eliıkokuz H, Eren M, Yılmaz U.** Clinical and electrocardiography changes in patients treated with capcitabine. *Chemotherapy* 2011; 57: 381-387 [PMID: 21997165] DOI: 10.1159/000331645

44 **Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Crucitti C, Goldhirsh A, Cicolla C, Roiía F; ESOM Guidelines Working Group.** Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESOM Clinical Practice Guidelines. *Ann Oncol* 2012; 23 Suppl 7: viii55-vii166 [PMID: 22997448] DOI: 10.1093/annonc/mds293

45 **Holubec L Jr, Topolcan O, Finek J, Salvet J, Svoboda T, Svobodova S, Mrazová P, Ludvíkova M.** Dynamic monitoring of cardio-specific markers and markers of thyroid gland function in cancer patients—a pilot study. *Anticancer Res* 2007; 27: 1883-1886 [PMID: 17649788]

46 **Ceyhan C, Meydan N, Barutca S, Tekten T, Onbasili AO, Oztürk B, Unal S, Bayrakkı A.** Influence of high-dose leucovorin and 5-fluorouracil chemotherapy regimen on P wave duration and dispersion. *J Clin Pharm Ther* 2004; 29: 267-271 [PMID: 15153089] DOI: 10.1111/j.1365-2710.2004.00556.x

47 **Depetris I, Marino D, Bonzano A, Cagnazzo C, Filippi R, Aglietta M, Leone F.** Fluoropyrimidine-induced cardiotoxicity. *Crit Rev Oncol Hematol* 2018; 124: 1-10 [PMID: 29548480] DOI: 10.1016/j.critrevonc.2018.02.002

48 **Turaj T, Agac MT, Aykan AC, Kul S, Akyüz AR, Gökdelen T, Gül İ, Cengiz E, Boyacı F, Erkan H, Akdemir R, Celik S.** Usefulfulness of Heart-Type Fatty Acid-Binding Protein and Myocardial Performance Index for Early Detection of 5-Fluorouracil Cardiotoxicity. *Angiology* 2017; 68: 52-58 [PMID: 26980771] DOI: 10.1111/j.1365-2710.2016.067516

49 **Wacker A, Lersch C, Scherpinski U, Reindl L, Seyfarth M.** High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. *Oncology* 2003; 65: 108-112 [PMID: 115990072334]

50 **Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakraborti S, Herrmann J, Lerman A, Grothey A.** 5-fluorouracil and cardiotoxicity: a review. *Ther Adv Med Oncol* 2018; 10: 1758835918780410 [PMID: 29977352] DOI: 10.1177/1758835918780410

51 **Layoun ME, Wickramarasinghe CD, Peralta MV, Yang EH.** Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management. *Curr Oncol Rep* 2016; 18: 35 [PMID: 27113369] DOI: 10.1007/s11912-016-0521-1

52 **Deboer G, Hilltop N, Cool M, Lambrecht G.** Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. *Clin Colorectal Cancer* 2013; 12: 8-14 [PMID: 23102544] DOI: 10.1016/j.clcc.2012.09.005

53 **Saif MW, Shah MM, Shah AR.** Fluoropyrimidine-associated cardiotoxicity: revisited. *Expert Opin Drug Saf* 2009; 8: 191-202 [PMID: 19390247] DOI: 10.1517/14740390902723961

54 **Clavel M, Sinéon P, Grivet B.** Cardiac toxicity of 5-fluorouracil. Review of the literature, 5 new cases. *Presse Med* 1988; 17: 1675-1678 [PMID: 2973029]

55 **Petrelli F, Barni S, Bertocchi P, Zaniboni A.** TAS-102, the first "cardio-gentle" fluoropyrimidine in the colorectal cancer landscape? *BMC Cancer* 2016; 16: 386 [PMID: 27377645] DOI: 10.1186/s12885-016-2409-8

56 **Pfeiffer P, Yilmaz M, Möller S, Zitnajak D, Krogh M, Petersen LN, Poulsen LØ, Winther SB, Thomsen KG.** Oxytrup C. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. *Lancet*
Deac AL et al. Fluoropyrimidine-induced cardiotoxicity

Oncol 2020; 21: 412-420 [PMID: 31999946 DOI: 10.1016/S1470-2045(19)30827-7]

57 Clasen SC, Ky B, O’Quinn R, Gaintonio B, Teitelbaum U, Carver JR. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm. J Gastrointest Oncol 2017; 8: 970-979 [PMID: 29293556 DOI: 10.21037/jgo.2017.09.07]

58 Avallone A, Di Gennaro E, Silvestro L, Iaffaioli VR, Badilllon A. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. Expert Opin Drug Saf 2014; 13: 115-129 [PMID: 24093908 DOI: 10.1517/14740338.2014.845167]

59 Ransom D, Wilson K, Fournier M, Simes RJ, Gelski V, Yip D, Tebbutt N, Karapetis CS, Ferry D, Gordon S, Price TJ. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. Ann Oncol 2014; 25: 117-121 [PMID: 24299960 DOI: 10.1093/annonc/mdt479]

59 Kelly C, Bhuva N, Harrison M, Buckley A, Saunders M. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. Eur J Cancer 2013; 49: 2303-2310 [PMID: 23583220 DOI: 10.1016/j.ejca.2013.03.004]

59 Ma WW, Saif MW, El-Rayes BF, Fakhri MG, Cartwright TH, Posey JA, King TR, von Borstel RW, Bamart MK. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer 2017; 123: 345-356 [PMID: 27622829 DOI: 10.1002/cncr.30321]

60 Ison G, Beaver JA, McGuinn WD Jr, Palmby TR, Dinin J, Charlab R, Marathe A, Jin R, Liu Q, Chen XH, Ysern X, Stephens O, Bar G, Wang Y, Dorff SE, Cheng J, Tang S, Sridhara R, Pierce W, McKee AE, Ibrahim A, Kim G, Pazdur R. FDA Approval: Uridine Triacetate for the Prevention and Treatment of Life-Threatening 5-Fluorouracil and Capecitabine Toxicity. J Oncal Pharm Pract 2020; 26: 747-753 [PMID: 31382864 DOI: 10.1177/1078155219865597]

61 Lampropoulou DI, Laschos K, Amylid AL, Angelaki A, Soupos N, Bounounopouropoulo S, Papadopoulou E, Nanou E, Zidianakis V, Nasioulas G, Fildissis G, Aravantinos G. Fluoropyrimidine-induced toxicity and DPD deficiency. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA? J Oncal Pharm Pract 2020; 26: 747-753 [PMID: 31382864 DOI: 10.1177/1078155219865597]

62 Saif MW, Smith M, Maloney A. The First Case of Severe Takotsubo Cardiomyopathy Associated with 5-Fluorouracil in a Patient with Abnormalities of Both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) Genes. Cureus 2016; 8: e783 [PMID: 27752409 DOI: 10.7759/cureus.783]
